VivoSim Labs Inc (VIVS) News & EventsVIVSVivoSim Labs Inc

VivoSim Files to Sell 9.41M Shares of Common Stock

VivoSim files to sell 9.41M shares of common stock for holders

VivoSim Announces First Commercial Sales of NAMkind Testing Services in China

VivoSim announced its first commercial sales in China, opening a new market for its NAMkind testing services. VivoSim delivers both toxicology and efficacy testing built on its 3D human tissue models of the liver and gastrointestinal tract. The two initial engagements, with a Shanghai-based oncology biotech and a large Chengdu-based pharmaceutical company, represent the company's first paid programs on the Chinese mainland and a milestone in VivoSim's expansion across Asia-Pacific.

VivoSim Anticipates Over 500% Revenue Growth in FY 2027

The company said, "VivoSim further announced that it anticipates significant revenue growth in Fiscal Year 2027 given its progress in marketing contract research services using NAMs models to pharmaceutical companies. The company anticipates over 500% revenue growth in the fiscal year, due to customer response to the predictive power of its NAMs models, which are building traction with a wide set of customers. VivoSim's superior results are achieved by a combination of the best biological model with the most representative primary human cell types, leveraging multiple endpoints as readouts for best prediction, and training AI prediction models with multiple endpoints that provide a rich data set, yielding high prediction accuracy. In addition to testing traditional small molecules, VivoSim is establishing competitive advantages across new biotech modalities such as antibody drug conjugates, antibodies, siRNA, and gene therapies. Many therapies still fail in human trials, most often on safety or efficacy. VivoSim's mission is to close gaps in the ability to predict outcomes before a drug enters expensive clinical trials. In recent months, VivoSim has demonstrated that its NAMkind Liver spheroid model achieved a predictive accuracy of 91%, with 90% sensitivity, 95% specificity, and 99% precision under repeat-dose conditions. The multi-endpoint profiling suite effectively minimized false negatives and successfully resolved intra-class toxicities, such as within thiazolidinediones. Similarly, the company's NAMkind Intestine models deliver greater than 90% sensitivity and overall accuracy for the prediction of drug-induced diarrhea."